A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH

NCT06692283 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business decision

Conditions

MASLD
MASH
NASH
Metabolic Dysfunction-Associated Steatotic Liver Disease
Metabolic Dysfunction-Associated Steatohepatitis
Nonalcoholic Steatohepatitis
Nonalcoholic Fatty Liver

Interventions

DRUG: denifanstat
DRUG: Placebo

Sponsor

Sagimet Biosciences Inc.